REVIVA PHARMA HLDGS INC
RVPH
RVPH was delisted on the 13th of May, 2026.
23 hedge funds and large institutions have $46.1M invested in REVIVA PHARMA HLDGS INC in 2019 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
16% more capital invested
Capital invested by funds: $39.6M → $46.1M (+$6.42M)
10% more funds holding
Funds holding: 21 → 23 (+2)
6.92% more ownership
Funds ownership: 46.3% → 53.21% (+6.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$3.45M |
| 2 |
CIM
Cowen Investment Management
New York
|
+$1.04M |
| 3 |
GCL
Glazer Capital LLC
New York
|
+$1.04M |
| 4 |
BFM
Boothbay Fund Management
New York
|
+$679K |
| 5 |
MSU
Mizuho Securities USA
New York
|
+$397K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
-$1.12M |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$1.05M |
| 3 |
BCM
Basso Capital Management
Stamford,
Connecticut
|
-$165K |
| 4 |
KIM
Karpus Investment Management
Pittsford,
New York
|
-$2.5K |
RVPH Hedge Fund Activity: Q4 2019 in Review
23 of the 5,093 institutional investors tracked by Wall St. Rank reported a position in REVIVA PHARMA HLDGS INC (RVPH) for Q4 2019, worth a combined $46.1M — up 16% from $39.6M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new RVPH positions and 1 closed out — a net gain of 2 holders — while 6 added to existing stakes and 3 trimmed.
The largest buyer was Polar Asset Management Partners, adding an estimated $3.45M. The largest seller was Cowen and Company, exiting entirely with an estimated $1.12M sold.
- 23 institutional investors held REVIVA PHARMA HLDGS INC (RVPH) as of Q4 2019, up from 21 in Q3 2019.
- Funds reported $46.1M of REVIVA PHARMA HLDGS INC stock for Q4 2019, up 16% quarter-over-quarter.
- 3 funds opened new REVIVA PHARMA HLDGS INC positions in Q4 2019 and 1 closed out, a net change of +2 holders.
- The largest REVIVA PHARMA HLDGS INC buyer in Q4 2019 was Polar Asset Management Partners, an estimated $3.45M added.
- The largest REVIVA PHARMA HLDGS INC seller in Q4 2019 was Cowen and Company, an estimated $1.12M sold.
Based on aggregated 13F filings for Q4 2019.